Skip to main content

Table 2 Correlation between the clinicopathological features and 2-year progression-free survival in combined hepatocellular cholangiocarcinoma

From: Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma

Variables No. of patients Cumulative
2- year progression-free survival rate
P HR (95% CI) P
Age
  < 60 28 38.5% 0.941   
60 24 35.6%
Gender
 Male 37 35.8% 0.097   
 Female 15 59.3%
Hepatitis B
 Negative 17 39.7% 0.632   
 Positive 35 44.9%
Hepatitis C
 Negative 36 42.5% 0.747   
 Positive 16 41.5%
Liver cirrhosis
 No cirrhosis 14 55.1% 0.479   
 Cirrhosis 38 39.2%
DM
 Negative 38 44.7% 0.575   
 Positive 14 37.5%
Gall stone
 Negative 47 45.2% 0.178   
 Positive 5 20.0%
CEA
  ≤ 5 45 44.3% 0.311   
  > 5 7 34.3%
CA-199
  ≤ 35 36 43.7% 0.535   
  > 35 16 19.3%
AFP
  ≤ 15 23 26.6% 0.978   
  > 15 29 43.5%
Histology grade
 Well or Moderate 38 44.9% 0.499   
 Poorly 14 40.8%
LVI
 Negative 33 50.4% 0.022*   
 Positive 19 15.0%
PNI
 Negative 46 44.1% 0.377   
 Positive 6 33.3%
Surgical margin
  <10 mm 35 35.4% 0.746   
  ≥ 10 mm 17 41.6%
T stage
 TI-II 42 52.3% < 0.001* 8.004 (2.869-22.336) < 0.001*
 TIII-IV 10 0%
N stage
 Negative 49 43.3% 0.223 4.701 (0.952-23.203) 0.057
 Positive 3 33.3%
AJCC staging
 I-II 40 53.2% < 0.001*   
 III-IV 12 8.3%
Midkine expression
 Negative 30 60.5% < 0.001* 4.238 (1.900-9.449) < 0.001*
 Positive 22 8.5%
  1. CI confidence interval, HR hazard ratio